Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022116 (
ischemia
)
91,303
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tissue kallikrein-related peptidases (KLKs) play important roles in acute cardiac injury and cardiac remodeling. However, the exact cardiac actions of
KLK8
have not been determined. Transgenic rat overexpressing
KLK8
was established to examine the role of
KLK8
in the heart. Cardiac injury was induced by
ischemia
/reperfusion (I/R) and examined by infarct size measurement and TUNEL staining. The molecular mechanisms were investigated in cultured neonatal rat cardiomyocytes (CMs). Western blot analysis was used to determine the protein levels.
KLK8
protein level was significantly increased in the cardiac ischemic risk area.
KLK8
overexpression mitigated I/R-induced cardiac injury, as evidenced by decreased infarct size and apoptosis in cardiac ischemic risk area in vivo. Via in vitro studies, it was found that
KLK8
overexpression attenuated the Hypoxia/Reoxygenation (H/R) injury in CMs; both B2R and PAR2 antagonist significantly attenuated
KLK8
-induced protective actions under H/R injury. Moreover,
KLK8
overexpressed CMs showed significant higher phosphorylation levels of Akt, ERK1/2 and PKA under H/R stimulation; B2R antagonist attenuated the phosphorylation levels of Akt and ERK1/2, while PAR2 antagonist attenuated the phosphorylation levels of PKA and ERK1/2.
KLK8
protects the heart against I/R-induced cardiac injury, which may represent a new therapeutic target in cardiac medicine.
...
PMID:Tissue kallikrein-related peptidase8 protects rat heart against acute ischemia reperfusion injury. 3144 61